DB15855Experimental
SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2 . It is the first COVID-19... It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy of Military Sciences.
What you can answer from here — as of October 29, 2025
Which companies are running trials of ARCoV, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account